Chimeric antigen receptors for adoptive T cell therapy in acute myeloid leukemia
Open Access
- 29 August 2017
- journal article
- review article
- Published by Springer Science and Business Media LLC in Journal of Hematology & Oncology
- Vol. 10 (1), 1-14
- https://doi.org/10.1186/s13045-017-0519-7
Abstract
Currently, conventional therapies for acute myeloid leukemia (AML) have high failure and relapse rates. Thus, developing new strategies is crucial for improving the treatment of AML. With the clinical success of anti-CD19 chimeric antigen receptor (CAR) T cell therapies against B-lineage malignancies, many studies have attempted to translate the success of CAR T cell therapy to other malignancies, including AML. This review summarizes the current advances in CAR T cell therapy against AML, including preclinical studies and clinical trials, and discusses the potential AML-associated surface markers that could be used for further CAR technology. Finally, we describe strategies that might address the current issues of employing CAR T cell therapy in AML.Keywords
Funding Information
- National Basic Research Program of China (2013CB932500)
- National Natural Science Foundation of China (60976004)
This publication has 124 references indexed in Scilit:
- Combinational Targeting Offsets Antigen Escape and Enhances Effector Functions of Adoptively Transferred T Cells in GlioblastomaMolecular Therapy, 2013
- Chimeric Antigen Receptor–Modified T Cells for Acute Lymphoid LeukemiaNew England Journal of Medicine, 2013
- TanCAR: A Novel Bispecific Chimeric Antigen Receptor for Cancer ImmunotherapyMolecular Therapy Nucleic Acids, 2013
- Inducible Apoptosis as a Safety Switch for Adoptive Cell TherapyNew England Journal of Medicine, 2011
- Case Report of a Serious Adverse Event Following the Administration of T Cells Transduced With a Chimeric Antigen Receptor Recognizing ERBB2Molecular Therapy, 2010
- Molecular immunology lessons from therapeutic T‐cell receptor gene transferImmunology, 2010
- Chimeric Receptors Containing CD137 Signal Transduction Domains Mediate Enhanced Survival of T Cells and Increased Antileukemic Efficacy In VivoMolecular Therapy, 2009
- CD47 Is Upregulated on Circulating Hematopoietic Stem Cells and Leukemia Cells to Avoid PhagocytosisCell, 2009
- CD47 Is an Adverse Prognostic Factor and Therapeutic Antibody Target on Human Acute Myeloid Leukemia Stem CellsCell, 2009
- CD96 is a leukemic stem cell-specific marker in human acute myeloid leukemiaProceedings of the National Academy of Sciences of the United States of America, 2007